Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy

Launched by MEDICAL UNIVERSITY OF GRAZ · Feb 7, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how being physically active throughout your life might affect the development of a heart condition called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). This condition can lead to heart failure, and the study aims to understand if regular exercise and activity can help prevent or reduce the risk of this disease. The trial is currently recruiting participants who are aged 60 and older, and who either have a confirmed diagnosis of wtATTR-CM or other related heart conditions, or are healthy without any heart issues.

If you join the trial, you'll be asked to complete questionnaires and possibly participate in interviews about your physical activity levels and health history. It's important to note that you need to be able to provide consent to participate and should not have severe chronic illnesses that limit your physical activity. This study hopes to gather valuable information that could help improve heart health in older adults, so your participation could make a difference.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Confirmed diagnosis of wtATTR-CM including sequencing of the TTR gene; or HF; or healthy proband without a diagnosis of heart disease
• • 2. Initial diagnosis of respective cardiac disease (wtATTR-CM, HF) after the 6th decade of life; or no cardiac disease (healthy control)
• • 3. Willingness and ability to provide signed informed consent form (ICF)
• • 4. Age \> 60 years
• Exclusion Criteria:
• • 1. History of severe chronic illness limiting the ability to perform physical activity during the 3rd to 6th decade
• • 2. A diagnosis of dementia or cognitive impairment
• • 3. Any other reason resulting in the inability to perform the questionnaire and/or interview
• • 4. Known disease-causing variant (pathogenic or likely-pathogenic) in the TTR gene